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Background: Given the high occurrence of prostate cancer worldwide and one of the major sources of the
discovery of new lead molecules being medicinal plants, this research undertook to investigate the possible
anti-cancer activity of two natural cycloartanes; cycloartane-3,24,25-diol (extracted in our lab from Tillandsia
recurvata) and cycloartane-3,24,25-triol (purchased). The inhibition of MRCKα kinase has emerged as a potential
solution to restoring the tight regulation of normal cellular growth, the loss of which leads to cancer cell formation.
Methods: Kinase inhibition was investigated using competition binding (to the ATP sites) assays which have been
previously established and authenticated and cell proliferation was measured using the WST-1 assay.
Results: Cycloartane-3,24,25-triol demonstrated strong selectivity towards the MRCKα kinase with a Kd50 of 0.26 μM
from a total of 451 kinases investigated. Cycloartane-3,24,25-triol reduced the viability of PC-3 and DU145 cell lines
with IC50 values of 2.226 ± 0.28 μM and 1.67 ± 0.18 μM respectively.
Conclusions: These results will prove useful in drug discovery as Cycloartane-3,24,25-triol has shown potential for
development as an anti-cancer agent against prostate cancer.
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Prostate cancer is the second most frequently diagnosed
cancer and sixth leading cause of cancer death in males,
worldwide [1]. The search for new molecules to combat
the rising cases of prostate cancer especially those re-
sistant to current chemotherapy calls for urgent action.
Medicinal plants have been one of the major sources for
the discovery of a number of current clinically used
anticancer drugs.
Previous research conducted in our lab demonstrated
the promising anti-cancer properties of Tillandsia recur-
vata L. (Bromeliaceae) commonly called the Jamaican
Ball Moss or the Old Man’s beard [2]. In an attempt to
identify the critical isolate from this plant that is respon-
sible for the observed said bioactivity, this research
uncovered the cycloartane, cycloart-23-ene-3,25-diol* Correspondence: simone.badal@uwimona.edu.jm
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reproduction in any medium, provided the or(Figure 1) [3]. Further literature research led us to a
closely related cycloartane, cycloartane-3,24,25-triol
(Figure 1), which had previously been extracted from the
Chrysanthemum morifolium plant and was shown to
possess promising chemopreventive properties [4].
Essential biological functions such as the provision of a
structural frame work and the driving force for cellular
motility and division are mediated by the actin cytoske-
leton in all eukaryotic cells. A comprehensive overview
of the biological processes that regulate the organization
of actin is of recent interest to the regime of cancer the-
rapy [5]. Members of the Rho GTPase family such as myo-
tonic dystrophy kinase-related Cdc42-binding kinases
(MRCKα) are key regulators of the actin cytoskeleton
and together with multiple target proteins safe guard the
tight regulation of normal cell growth and differentiation
[6,7]. In the event of genomic alterations or carcinoge-
nesis, eukaryotic cells become predispose to rapid and
uncontrollable growth as evidenced by the elevated levels
of LIMK1 kinase expressed in prostate cancer, a kinasetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and







Figure 1 Structures of cycloartanes.
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son that inhibitors of these biochemical entities are
thought to restore normal cell proliferation and provide
a key solution to cancer treatment. The aim of this study
therefore was to confirm the promising in vitro anti pros-
tate cancer activity of 2 cycloartane isolates and their ef-
fect on prostate cancer related kinases, namely MRCKα.
Results and discussion
GTPases are activated by GTP exchange factors (GEFs)
and down-regulated by GTPase-activating proteins
(GAPs). Prolonged activation of these molecular entities
can initiate a series of signal transduction pathways
that can impinge on a number of cellular processes [7].
Amongst the transducers of these signals are protein
kinases and increase Rho signalling has been associated
with tumour development and/or progression from va-
rious origins [8]. The MRCKα kinase, an effector of CDC42
GTPase with functional overlap with ROCK1/2, has also
been suggested to have a role in tumour progression [9]
and/or invasion [10].
Given the reported elevated levels of MRCKα in cancer
tumours relative to normal neighbouring tissues [9,10],
the potent selective inhibitory (Kd50 = 0.26 μM) properties
of cycloartane-3,24,25-triol towards the MRCKα kinase
of a total of 451 kinases tested makes it a promising can-
didate for further investigation into the treatment of
prostate cancer. Not only did this isolate inhibit the
MRCK kinase but it also reduced the viability of the PC-
3 cell line with an IC50 value of 2.226 ± 0.28 μM (Table 1).
This indicates that cycloartane-3,24,25-triol is more ef-
fective than other promising leads towards this cell line
as Terracciano et al., [11] investigated an inhibitor of this
cell line and only 38% inhibition was observed at 4 μM.
In addition to reducing the viability of the PC-3 cell line,Table 1 IC50 results of WST-assay for PC-3 and DU145
Antiproliferation activity (IC50 : μM) Kinase inhibition (Kd50 μM)
PC-3 Du145 MRCKα
2.226 ± 0.28 1.67 ± 0.18 0.26cycloartane-3,24,25-triol also reduced the viability of
another prostate cancer cell line DU145 with an IC50
value of 1.67 ± 0.18 μM (Table 1). This observed bio-
activity makes this isolate even more relevant in pros-
tate cancer treatment than omega-3FAs; docosaheenois
acid (DHA) and eicosapentaenoic acid (EPA) that both
reduced the viability of PC-3 cell line comparable to
cycloartane-3,24,25-triol but showed no impact towards
DU145 cells [12].
Conclusions
We report for the first time this inhibition of MRCKα
kinase inhibition by cycloartane-3,24,25-triol. Of the
451 kinases, cycloartane-3,24,25-triol selectively inhibited
MRCKα with greater potency than other potential che-
motherapeutics. Our findings show that the bioactivity of
this isolate not only inhibits MRCKα known to be asso-
ciated with prostate cancer, but also reduced the viability
of two prostate cancer cell lines, PC-3 and DU145 impli-




The Cayman’s WTS-1assay kit which was used for the
cell proliferation assay and kinase inhibition assay chemi-
cals were purchased from Cayman Chemical Company.
Cell lines and culture medium
All cell lines with their respective media and supple-
ments were obtained from ATCC (Manassas, VA, USA).
Cell proliferation
The cells (PC-3 and DU145) were maintained in minimum
essential media (MEM) supplemented with 10% foetal
calf serum (FCS), 20 mM l-glutamine, 2% penicillin–
streptomycin, and 0.2% gentamicin. Cells were main-
tained at 37°C with 5% CO2 in Corning 75 cm
3 culture
flasks. Cells were trypsinized and plated at the appropriate
density (500–2000 cells/well in log phase 72 h post drug
addition) into 96 well plates in media for approximately
Figure 2 How the KinomeScan assay works (Courtesy of DiscoveRx).
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cycloart-23-ene-3,25-diol and cycloartane, cycloart-23-ene-
3,25-triol for 72 h. The compounds were solubilized in
DMSO (>0.1%). Following the appropriate treatments,
cell proliferation was measured using the WST-1
(4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,
3-benzene disulfonate) (Roche) colorimetric assay accord-
ing to the manufacturer’s instructions [13]. All assays
were performed in duplicates and were monitored spectro-
photometrically at 450 nm/690 nm (Synergy HT 96-well
Plate Reader - BIO-TEK). Cell viability was assessed as
percent of drugs relative to vehicle solvent-treated control.
IC50 values were determined from the extract dose versus
control growth curves using Graph Prism software.
Kinase inhibition assay
Competition binding assays were established, authenti-
cated and executed as described previously [14,15]. For
most assays, kinases were fused to T7 phage strains [14]
and for the other assays, kinases were produced in
HEK-293 cells after which they were tagged with DNA
for quantitative PCR detection (data not shown). In
general, full-length constructs were used for small, single
domain kinases, and catalytic domain constructs for
large multi-domain kinases. The binding assays utilized
streptavidin-coated magnetic beads treated with biotiny-
lated small molecule ligands for 30 minutes at room
temperature which generated affinity resins for the kinase
assays. The liganded beads were blocked with excess bio-
tin and washed with blocking buffer (SeaBlock (Pierce),
1% BSA, 0.05% Tween 20, 1 mM DTT) to remove un-
bound ligand and to reduce non-specific phage binding.
Binding reactions were assembled by combining kinases,
liganded affinity beads, and test compounds in 1x bind-
ing buffer (20% SeaBlock, 0.17x PBS, 0.05% Tween 20,
6 mM DTT). Test compounds were prepared as 40x
stocks in 100% DMSO and diluted directly into the assay
(Final DMSO concentration = 2.5%). All reactions were
performed in polypropylene 384- well plates in a final
volume of 0.04 ml. The assay plates were incubated at
room temperature with shaking for 1 hour and the affinity
beads were washed with wash buffer (1x PBS, 0.05%
Tween 20). The beads were then re-suspended in elution
buffer (1× PBS, 0.05% Tween 20, 0.5 μM non-biotinylatedaffinity ligand) and incubated at room temperature with
shaking for 30 minutes. The kinase concentration in the
eluates was measured by quantitative PCR and Table 1
presents kd50 for kinase interaction with the test com-
pound. These were determined using a standard dose
response curve using the hill equation. Curves were fitted
using a non-linear least square fit with the Levenberg-
Marquardt algorithm. Figure 2 illustrates the kinase inter-
action process.
Plant material: Tillandsia recurvata (extraction and
isolation)
The whole T. recurvata plant was collected from trees and
electricity poles at Kingston, Jamaica. A voucher speci-
men of the plant was identified at the Institute of Jamaica
Herbarium where it is deposited with Accession Number:
IJ 3411. The collected plant material was air dried,
pulverized into powder. 2.3 kg of Ball Moss biomass was
extracted twice with 5 L of Chloroform. The filtrate was
dried in a rotavapor to obtain a dark green residue
(87.6 g).
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